SequelSEC

GT Biopharma, Inc. GTBP

Pharmaceutical Preparations · CIK 0000109657 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2021-09-30
Operating income
-$5.95M
Fiscal year ended 2021-09-30
Free cash flow
Unavailable
Fiscal year ended 2021-09-30

GT Biopharma, Inc. (GTBP) reported revenue of $0 and net income of -$5.45M for the fiscal year ended 2021-09-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from GT Biopharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

GT Biopharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-06-30
Revenue$0$0$0$0$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0Unavailable$0$0
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0Unavailable$0$0
Operating income-$5.95M-$4.38M-$29.00M-$2.19M-$1.94M-$1.56M$1.07M$20.11M-$4.06M-$5.16M
Net income-$5.45M-$4.86M-$29.68M-$6.29M-$2.88M-$17.42M-$1.71M-$34.14M-$4.51M-$9.08M
Research & development$1.01M$639.00K$1.64M$233.00K$84.00K$12.00K$324.00K$833.00K$834.00K$3.25M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableshares 70.08MUnavailableshares 51.09MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailable-$2.88M-$8.78M-$1.71M-$34.14M-$4.51M-$9.08M
Income tax expenseUnavailableUnavailableUnavailableUnavailable$0$0$0$0$0$0
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$-0.02Unavailable$-0.09$50,117,977.00
Selling, general & administrative$4.95M$3.74M$27.36M$1.96M$2.03M$1.55M$746.00K$6.57M$3.22M$1.91M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

GT Biopharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-06-30
Cash & equivalentsUnavailable$39.50M$27.56M$5.30M$350.00K$851.00K$5.00K$28.00K$51.00K$1.10M
Total assetsUnavailableUnavailableUnavailable$5.66M$917.00K$1.06M$295.00K$396.00K$25.54M$255.01M
Current assets$35.80M$39.57M$27.64M$5.66M$833.00K$971.00K$188.00K$274.00K$78.00K$1.10M
Total liabilitiesUnavailableUnavailableUnavailableUnavailable$30.69MUnavailable$21.15M$19.71M$15.52M$8.95M
Current liabilities$3.92M$3.28M$3.63M$35.09M$30.69M$28.56M$21.15M$19.71M$15.52M$8.95M
Total equity incl. NCI$31.88M$36.29M$24.02M-$29.43M-$29.78M-$27.50M-$20.86M-$19.31M$10.02M$246.06M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.80M$1.50M$2.38M$2.24M$2.17M$2.00M$2.37M$1.94M$1.90M$1.89M

Cash flow

GT Biopharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-06-30
Operating cash flow-$3.93M-$4.29M-$3.68M-$1.93M-$1.70M-$3.41M-$223.00K-$2.70M-$961.00K-$1.77M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0$0
Investing cash flowUnavailableUnavailableUnavailable$0$0UnavailableUnavailable$200.00K$0$0
Financing cash flow$137.00K$16.24M$25.94M$6.87M$1.20M$4.26M$200.00K$2.48M$952.00K$0
Net change in cash-$29.82M$11.95M$22.26M$4.95M-$501.00K$846.00K-$23.00K-$23.00K-$9.00K-$1.77M
Stock-based compensation$1.96M$327.00K$8.50M$269.00K-$147.00K$147.00K$0$2.74M$2.56M$3.43M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

GT Biopharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-06-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$1.77M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio9.13x12.08x7.62x0.16x0.03x0.03x0.01x0.01x0.01x0.12x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GTBP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-Q/A · Filed 2026-03-06View SEC filing
10-Q/A · Filed 2026-03-06View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2017-09-30

Difference 253887000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2017-03-31

Difference 17941000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.